Growing community of inventors

Hong Kong, China

Zhiyuan Li

Average Co-Inventor Count = 13.00

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 12

Zhiyuan LiWei Zhu (4 patents)Zhiyuan LiQingxia Wang (4 patents)Zhiyuan LiXin Yao (4 patents)Zhiyuan LiYutian Wei (4 patents)Zhiyuan LiYanfeng Li (4 patents)Zhiyuan LiYihong Yao (4 patents)Zhiyuan LiLin Zhu (4 patents)Zhiyuan LiJiaqi Huang (4 patents)Zhiyuan LiShigui Zhu (4 patents)Zhiyuan LiJiaping He (4 patents)Zhiyuan LiAnyun Ma (4 patents)Zhiyuan LiLi Zhang (3 patents)Zhiyuan LiFang Liu (1 patent)Zhiyuan LiLin Zhu (8 patents)Zhiyuan LiZhiyuan Li (4 patents)Wei ZhuWei Zhu (73 patents)Qingxia WangQingxia Wang (17 patents)Xin YaoXin Yao (15 patents)Yutian WeiYutian Wei (12 patents)Yanfeng LiYanfeng Li (12 patents)Yihong YaoYihong Yao (10 patents)Lin ZhuLin Zhu (10 patents)Jiaqi HuangJiaqi Huang (10 patents)Shigui ZhuShigui Zhu (9 patents)Jiaping HeJiaping He (6 patents)Anyun MaAnyun Ma (4 patents)Li ZhangLi Zhang (13 patents)Fang LiuFang Liu (56 patents)Lin ZhuLin Zhu (8 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Cellular Biomedicine Group Hk Limited (2 from 7 patents)

2. Cellular Biomedicine Group, Inc. (2 from 4 patents)


4 patents:

1. 11618778 - Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

2. 11608369 - Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

3. 11472858 - Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

4. 11066457 - Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/4/2025
Loading…